AlphaMaven AlphaMaven

Frazier Healthcare Partners Completes Majority Investment in ATUM

Reported by Business Wire
Nov 17, 2026· 2 min read
Save Post LinkedIn Email
Key Takeaways
  • • Frazier Healthcare Partners, a healthcare-exclusive private equity firm, announced completion of a majority investment in ATUM, a bioengineering company, alongside co-investors including Frazier Life Sciences and ATUM's existing founders and management.
  • • ATUM, originally founded as DNA2.0 in 2003, combines machine learning with gene design, protein optimization, and cell line development through its Leap-In Transposase platform.
  • • Milton Boyer, a Frazier Executive in Residence, will join ATUM's board as Executive Chair, while Jeremy Minshull continues as Chief Executive Officer.
  • • Baird acted as ATUM's exclusive financial advisor and Paul Hastings as its legal counsel; William Blair and Goodwin Procter advised Frazier.
Summary
Seattle-based Frazier Healthcare Partners ("Frazier"), a private equity firm focused exclusively on healthcare, has completed its majority investment in ATUM, according to a Business Wire release. The transaction was completed in partnership with co-investors, including Frazier Life Sciences, and ATUM's existing founders and management team. The release did not disclose the transaction value.

ATUM, which is based in Newark, California, was originally founded as DNA2.0 in 2003. The company describes itself as having pioneered the modern bioengineering landscape by pairing machine learning with gene design, protein optimization, and cell line development via its Leap-In Transposase platform. According to the company, its integrated solutions routinely enhance expression titers and support reliable scale-up to manufacturing, positioning it as a technology partner to major players across the biopharma sector.

Under the new structure, Frazier Executive in Residence Milton Boyer will join the board as Executive Chair, while Jeremy Minshull will continue to lead ATUM as Chief Executive Officer. Minshull said ATUM's growth has been driven by deep customer collaborations and that the partnership will allow the company to expand capacity, grow infrastructure, and innovate faster while remaining true to its mission and scientific values.

Jeremy Janson, Principal at Frazier Healthcare Partners, said the firm has a long history of investing in pharmaceutical services but rarely sees the combination of scientific leadership and market opportunity found at ATUM. Boyer characterized the deal as bringing together Frazier's Center of Excellence, Executive in Residence program, and life sciences expertise with a company that has set the benchmark for scientific leadership, with the aim of expanding ATUM's biologics development platform.

Baird served as ATUM's exclusive financial advisor and Paul Hastings provided legal counsel to the company. Frazier was advised by William Blair and Goodwin Procter. Frazier, founded in 1991, reports having raised over $11 billion of capital for private funds and co-investment opportunities and having invested in more than 200 companies, with offices in Seattle and New York City.

Go deeper than the headline

Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.

Start your free 7-day trial

Sources

1 outlet

AlphaMaven summarised this story from the reporting below. Each link opens the original article.

Business Wire Frazier Healthcare Partners Completes Majority Investment in ATUM